COCP Cocrystal Pharma Inc
16,244
$2.04
$0.0855
(4.01%)
| Watchers | 16,244 |
| 52-Wk Low | $1.33 |
| 52-Wk High | $3.29 |
| Market Cap | $21.67M |
| Volume | 31,061.00 |
| 52-Wk High | $3.29 |
| 52-Wk Low | $1.33 |
Cocrystal Pharma (NASDAQ:COCP) Stock Rating Reaffirmed by HC WainwrightTicker Report • about 2 months ago
HC Wainwright restated their buy rating on shares of Cocrystal Pharma (NASDAQ:COCP - Free Report) in a report published on Thursday morning, Benzinga reports. They currently have a $10.00 target...
Share to Feed
Cocrystal Pharma, Inc. (NASDAQ:COCP - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Cocrystal Pharma in a research report...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
FDA feedback following the Company's submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza A clinical trial with oral CC-42344, a broad-spectrum...
Cocrystal Pharma GAAP EPS of -$1.87...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
COCP stock results show that Cocrystal Pharma beat analyst estimates for earnings per share the fourth quarter of 2023.
The post COCP...
Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash., March 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ( Cocrystal or...
LOS ANGELES, CA / ACCESSWIRE / March 5, 2024 / Planet MicroCap today published a new Video Interview with Jim Martin, Co-CEO and CFO, from Cocrystal Pharma, Inc. (NASDAQ:COCP), a clinical-stage...